ROIV vs. VRTX: Roivant Sciences vs. Vertex Pharmaceuticals Stock Comparison

Company Profile

Roivant Sciences (ROIV) and Vertex Pharmaceuticals (VRTX) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Vertex Pharmaceuticals (VRTX) has more than two decades of public-market history since July 24, 1991, whereas Roivant Sciences (ROIV) listed on December 8, 2020 and has a much shorter record to draw on.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Roivant Sciences (ROIV) reports a negative ROE of -8.52%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Vertex Pharmaceuticals (VRTX) reports 20.80%, ranking against industry peers normally.

Vertex Pharmaceuticals (VRTX) at 30.70% converts revenue to bottom-line profit above its industry’s benchmark range, while Roivant Sciences (ROIV) at 0.00% keeps roughly the typical share for its industry.

Roivant Sciences (ROIV) reports a negative operating margin of -25,408.11%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Vertex Pharmaceuticals (VRTX) reports 35.57%, ranking against industry peers normally.

Profitability Metrics

Growth

Vertex Pharmaceuticals (VRTX) at 8.90% is around its peer norm for revenue growth, while Roivant Sciences (ROIV) at -71.57% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Neither Roivant Sciences (ROIV) nor Vertex Pharmaceuticals (VRTX) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Roivant Sciences (ROIV) at 16.72 carries current ratio above its industry’s typical mid-range, while Vertex Pharmaceuticals (VRTX) at 2.34 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.

Both Roivant Sciences (ROIV) at 0.02 and Vertex Pharmaceuticals (VRTX) at 0.31 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Roivant Sciences (ROIV) nor Vertex Pharmaceuticals (VRTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Roivant Sciences (ROIV) nor Vertex Pharmaceuticals (VRTX) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Vertex Pharmaceuticals (VRTX) trades at 35.21 times trailing earnings, ranked against its peers, while Roivant Sciences (ROIV) has no P/E ratio this period.

Vertex Pharmaceuticals (VRTX) at 10.71 prices around its industry’s typical P/S ratio, while Roivant Sciences (ROIV) at 3,728.61 clears its benchmark range — ROIV looks notably rich on sales.

Both Roivant Sciences (ROIV) at 6.64 and Vertex Pharmaceuticals (VRTX) at 6.63 carry a premium to book value versus peers, sitting in the upper P/B ratio quartile of their industries.

Valuation Metrics